Monday, February 24, 2014
Exelixis Inc., of South San Francisco, reported net revenues of $4.3 million for the fourth quarter and $31.3 million for the full year, including net product revenues of $4.3 million and $15 million, respectively, for the fourth quarter and full year sales of Cometriq (cabozantinib), which was launched in January 2013 for medullary thyroid cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.